Madelyn Shiplov Price, MCD/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17352 Main St N, Blountstown, FL 32424 Phone: 850-674-4300 Fax: 850-674-4305 |
Mrs. Amy Kleinrichert Hurt, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 19977 N.e. Marie Ave., Blountstown, FL 32424 Phone: 850-674-3885 |
Marie Castaneda, MS, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16690 Sw Chipola Rd, Blountstown, FL 32424 Phone: 850-674-4311 |
News Archive
New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated plans to establish an office in China to facilitate the Company's drug development and clinical trials in that country.
Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.
British scientists have developed the first pair of bionic glasses that could help thousands of legally blind people. These glasses using tiny cameras and software technology from video games, alert the wearer to objects in their surroundings using flashing lights.
› Verified 5 days ago